The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC).
Krastan B. Blagoev
No relevant relationships to disclose
Mauricio Emmanuel Burotto Pichun
No relevant relationships to disclose
Julia Wilkerson
No relevant relationships to disclose
Montserrat Blanco-Codesido
No relevant relationships to disclose
Edward Espinal Dominguez
No relevant relationships to disclose
Pilar Garcia-Alfonso
No relevant relationships to disclose
Antonio Tito Fojo
No relevant relationships to disclose